CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...

Dr Woolf said: “I am delighted that Jeff has had such a positive response to his treatment and is now cancer-free six years ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

The field of Cancer Immunity & Immunotherapy is entering an exciting new phase. While Volume I (see here) of this Research Topic highlighted broad ...

In the Phase III IMforte trial, Tecentriq (atezolizumab) and Zepzelca (lurbinectedin) reduced the risk of disease progression ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

BeOne Medicines' robust financial outlook is driven by zanubrutinib's rapid sales growth and anticipated positive cash flow.

END SEPSIS proudly announces the reintroduction of the SEPSIS Act (S.1929), a bipartisan bill that marks a significant step toward creating a comprehensive national response to the sepsis crisis.

Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing (NGS) ...

Accuray Incorporated  today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately ...

Abstract Title: Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.